Primecap Management Co. CA Takes $4.64 Million Position in Zentalis Pharmaceuticals, Inc. $ZNTL

Primecap Management Co. CA bought a new position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) during the 2nd quarter, HoldingsChannel reports. The fund bought 957,420 shares of the company’s stock, valued at approximately $4,643,000.

A number of other hedge funds also recently modified their holdings of the stock. AQR Capital Management LLC raised its stake in Zentalis Pharmaceuticals by 177.6% in the first quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock valued at $985,000 after purchasing an additional 396,233 shares in the last quarter. Millennium Management LLC raised its position in shares of Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after buying an additional 2,111,951 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $37,000. Sei Investments Co. lifted its holdings in shares of Zentalis Pharmaceuticals by 373.1% during the 2nd quarter. Sei Investments Co. now owns 167,100 shares of the company’s stock worth $194,000 after acquiring an additional 131,780 shares during the period. Finally, Jane Street Group LLC boosted its position in shares of Zentalis Pharmaceuticals by 346.3% during the 2nd quarter. Jane Street Group LLC now owns 664,061 shares of the company’s stock worth $770,000 after acquiring an additional 515,257 shares in the last quarter.

Insider Buying and Selling

In related news, major shareholder Group Walters bought 4,335,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were purchased at an average price of $3.50 per share, for a total transaction of $15,172,500.00. Following the completion of the transaction, the insider directly owned 17,844,973 shares of the company’s stock, valued at approximately $62,457,405.50. This represents a 32.09% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 3.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ZNTL shares. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Mizuho started coverage on Zentalis Pharmaceuticals in a report on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Finally, Rodman & Renshaw initiated coverage on Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They set a “buy” rating and a $11.00 price target for the company. Four analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $6.75.

Zentalis Pharmaceuticals Trading Up 0.3%

ZNTL stock opened at $3.89 on Thursday. The firm has a 50-day moving average price of $4.36 and a 200-day moving average price of $3.71. Zentalis Pharmaceuticals, Inc. has a 12 month low of $1.21 and a 12 month high of $6.95. The stock has a market capitalization of $278.80 million, a P/E ratio of -1.99 and a beta of 1.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.10). As a group, equities analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.14 EPS for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.